Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077622 | 1.00 | MAPT (0.56) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL13688924 | 0.85 | MAPT (0.52) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL8213285 | 0.84 | MAPT (0.45) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL6092331 | 0.82 | JUN (0.51) | MAPTKDM4EJUNNFKB1CYP17A1 | |
| SCHEMBL8068014 | 0.82 | JUN (0.51) | MAPTKDM4EJUNNFKB1CYP17A1 | |
| SCHEMBL6091145 | 0.82 | GABBR2 (0.53) | MAPTKDM4EP2RX7KMT2AMEN1 | |
| SCHEMBL12040547 | 0.82 | GABBR2 (0.53) | MAPTKDM4EP2RX7KMT2AMEN1 | |
| SCHEMBL29514819 | 0.77 | RAB9A (0.73) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL485944 | 0.77 | RAB9A (0.73) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL485947 | 0.77 | RAB9A (0.73) | MAPTRAB9AKDM4ENPC1JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | claimed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2257528-A2 | 1 IBETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106817-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008035049-A1 | ADAMANTANYL-(CYCLOPROPYL)-KETONES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
| EP-0640072-B1 | Derivatives of pyridine as hydroxylase and lyase inhibitors | BTG INT LTD (GB) | 2000-08-23 | — | — | EP | disclosed |
| US-5595995-A | ANTICARCINOGENIC AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-01-21 | — | — | US | disclosed |
| EP-0640072-A1 | SUBSTITUTED PYRIDINES, THEIR PREPARATION AND PHARMACEUTICAL USE | BTG INTERNATIONAL LIMITED (GB) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023375-A1 | SUBSTITUTED PYRIDINES, THEIR PREPARATION AND PHARMACEUTICAL USE | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | MAPT 87/4885RAB9A 3821/4885KDM4E 3234/4885 |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | MAPT 4681/4885RAB9A 3505/4885KDM4E 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.